Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

RheumPAC’s Role in the ACR’s Advocacy Efforts

From the College  |  March 7, 2024

In an election year, it is critical that the ACR’s non-partisan political action committee be well positioned to support our congressional champions. Learn more about RheumPAC and its role in the ACR’s advocacy efforts.

Updates from the ACR Insurance Subcommittee

From the College  |  March 7, 2024

The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices, including issues related to biosimilar use, in-office treatments and the new G2211 code.

The ACR Gets Rheumatologists Paid More

Christina D. Downey, MD  |  February 20, 2024

The implementation of the new G2211 code on Jan. 1 increases reimbursement for rheumatology visits, but the ACR continues to fight for retroactive repayment of the across-the-board Medicare physician reimbursement cuts implemented at the same time, as well as structural changes to the program to make serving Medicare patients sustainable for rheumatologists in the long term.

3 AC&R Study Summaries: Prescribing Patterns, PMR & Glucocorticoids, & Infection Screening

Arthritis Care & Research  |  February 9, 2024

A Shift in Prescribing Patterns Safety issues prompt discontinuation of tofacitinib By Stephanie Song, MD, & Joshua F. Baker, MD, MSCE Why was this study done? The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE) and malignancy associated with use of Janus kinase inhibitors (JAKi). We sought to determine the impact of safety…

2024 State Legislative Preview

Joseph Cantrell, JD  |  February 6, 2024

With state legislatures now in session, the ACR is working with our partners to ensure that the voice of the rheumatology community is heard. Here is a look at some of the bills we are monitoring and the trends we expect to play out over the 2024 legislative calendar.

Support RheumPAC to Keep Rheumatology in Healthcare Policy Conversations

From the College  |  February 3, 2024

2024 is an election year, which means it is more critical than ever that RheumPAC is well equipped to support campaigns and take part in important healthcare discussions on Capitol Hill.

The ACR Advocates for G2211 Reimbursement under Medicare Advantage & Commercial Plans

From the College  |  February 3, 2024

The ACR is reaching out to Medicare Advantage and commercial payers to ensure appropriate reimbursement for the new complex care add-on code, G2211, implemented for outpatient office visits starting Jan. 1, 2024.

Study Assesses Sarilumab for Polymyalgia Rheumatica

Ruth Jessen Hickman, MD  |  January 25, 2024

In an ACR Convergence 2022 session, Robert Spiera, MD, director of the Scleroderma, Vasculitis, and Myositis Center at the Hospital for Special Surgery, New York City, discussed the use of sarilumab as a potential glucocorticoid-sparing therapy in a phase 3 study in patients with treatment-refractory polymyalgia rheumatica (PMR), one of the most common inflammatory diseases…

FDA Approves Sarilumab for Adults with Glucocorticoid-Resistant Polymyalgia Rheumatica

Michele B. Kaufman, PharmD, BCGP  |  January 25, 2024

On Feb. 28, 2023, the U.S. Food & Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with polymyalgia rheumatica (PMR) for whom glucocorticoids have proved inadequate or who cannot tolerate a glucocorticoid taper.1,2 Sarilumab is an interleukin (IL) 6 receptor antagonist. In May 2017, the FDA initially approved the agent for the…

How to Treat Refractory Polymyalgia Rheumatica

Katie Robinson  |  January 25, 2024

Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…

  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 244
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences